Tango Therapeutics, Inc.
TNGXDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
How TNGX's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Tango Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Tango Therapeutics, Inc.'s (TNGX) pipeline across Phase 2. Its lead program is TNG260 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tango Therapeutics, Inc.'s next FDA catalyst?→
Tango Therapeutics, Inc.'s (TNGX) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TNGX biotech catalysts?→
Add TNGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tango Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.